Clinical trials: CNS Tumor, Adult
Brain and Central Nervous System Tumors
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00027625
- Testing
- gefitinib, temozolomide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cognitive/Functional Effects, Metastatic Cancer
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity
- Trial name
- NCT01372774
- Testing
- stereotactic radiosurgery, whole-brain radiation therapy
- Where
- 37 sites in United States
- Volunteers
- 194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer Brain, Pediatric Cancer
Memory Neuroimaging in Children, Adolescents and Young Adults Following Pediatric Cancer
Brain tumours are the leading cause of cancer-related death and morbidity in children, adolescents and young adults. The brain is also one of the most sensitive organs to treatments used in pediatric oncology, even for cancers…
- Trial name
- IMPALA (NCT04324450)
- Testing
- MRI, Cognitive assessment
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00720356
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Glioblastoma Multiforme
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112502
- Testing
- Celecoxib, Isotretinoin, Temozolomide
- Where
- 12 sites in United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Lesion, Brain Tumor Adult
Handheld Dynamometer During Awake Craniotomy Pilot
The primary purpose of this study is to assess the feasibility, safety and reliability of the use of handheld dynamometry in evaluating intraoperative motor function for patients undergoing awake craniotomy for the resection of…
- Conditions
- Brain Lesion, Brain Tumor Adult, Brain Tumor
- Trial name
- NCT04742231
- Testing
- Hand-held dynamometer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Adult Solid Neoplasm, Childhood Solid Neoplasm
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or…
- Conditions
- Adult Solid Neoplasm, Childhood Solid Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT02116777
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Where
- 22 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Astrocytoma
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Background: Zotiraciclib (TG02) is an investigational drug that penetrates the blood-brain barrier and might treat brain tumors. Temozolomide (TMZ) is a drug used to treat brain tumors.
- Conditions
- Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma
- Trial name
- NCT02942264
- Testing
- Zotiraciclib (TG02), Temozolomide (TMZ)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating patients who have…
- Trial name
- NCT00002988
- Testing
- carmustine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Brain Metastases, Adult
Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery
Brain metastases (BM) represents a devastating clinical reality, carrying an estimated survival time of less than one year. Number of reasons, including complicated tumor biology and difficulties in modeling metastatic cancer in…
- Trial name
- NCT04785521
- Testing
- Stereotactic radiosurgery, Blood samples
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01122901
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in patients with recurrent high grade glioma and in patients with low grade glioma.
- Trial name
- NCT01229644
- Testing
- Crenolanib (CP-868,596)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Brain and Central Nervous System Tumors
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005081
- Testing
- O6-benzylguanine, carmustine
- Where
- United States
- Sponsor
- Duke University
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Brain and Central Nervous System Tumors, Cerebral Edema
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
RATIONALE: Giving the herb Boswellia serrata after surgery and radiation therapy may slow the growth of any remaining tumor cells.
- Trial name
- NCT00243022
- Testing
- Boswellia serrata extract, cyanocobalamin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ali Altunkaya
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.